PL2459553T3 - Furazanobenzimidazole jako proleki do leczenia chorób nowotworowych lub autoimmunizacyjnych - Google Patents
Furazanobenzimidazole jako proleki do leczenia chorób nowotworowych lub autoimmunizacyjnychInfo
- Publication number
- PL2459553T3 PL2459553T3 PL10740196T PL10740196T PL2459553T3 PL 2459553 T3 PL2459553 T3 PL 2459553T3 PL 10740196 T PL10740196 T PL 10740196T PL 10740196 T PL10740196 T PL 10740196T PL 2459553 T3 PL2459553 T3 PL 2459553T3
- Authority
- PL
- Poland
- Prior art keywords
- furazanobenzimidazoles
- prodrugs
- autoimmune diseases
- treat neoplastic
- neoplastic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09166469 | 2009-07-27 | ||
| EP10740196.0A EP2459553B1 (en) | 2009-07-27 | 2010-07-26 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
| PCT/EP2010/060803 WO2011012577A1 (en) | 2009-07-27 | 2010-07-26 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2459553T3 true PL2459553T3 (pl) | 2015-03-31 |
Family
ID=41226617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10740196T PL2459553T3 (pl) | 2009-07-27 | 2010-07-26 | Furazanobenzimidazole jako proleki do leczenia chorób nowotworowych lub autoimmunizacyjnych |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8802858B2 (pl) |
| EP (1) | EP2459553B1 (pl) |
| JP (1) | JP5576485B2 (pl) |
| KR (1) | KR101758400B1 (pl) |
| CN (1) | CN102471329B (pl) |
| AU (1) | AU2010277688B2 (pl) |
| BR (1) | BR112012001817B8 (pl) |
| CA (1) | CA2767875C (pl) |
| CY (1) | CY1115809T1 (pl) |
| DK (1) | DK2459553T3 (pl) |
| EA (1) | EA021380B1 (pl) |
| ES (1) | ES2524119T3 (pl) |
| HK (1) | HK1166316A1 (pl) |
| HR (1) | HRP20141120T1 (pl) |
| IL (1) | IL217195A (pl) |
| MX (1) | MX336240B (pl) |
| NZ (1) | NZ597376A (pl) |
| PL (1) | PL2459553T3 (pl) |
| PT (1) | PT2459553E (pl) |
| RS (1) | RS53679B1 (pl) |
| SI (1) | SI2459553T1 (pl) |
| TW (1) | TWI457337B (pl) |
| UA (1) | UA106763C2 (pl) |
| WO (1) | WO2011012577A1 (pl) |
| ZA (1) | ZA201200228B (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2666014B1 (en) | 2011-01-21 | 2016-10-05 | Basilea Pharmaceutica AG | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles |
| PT2666015T (pt) * | 2011-01-21 | 2017-03-22 | Basilea Pharmaceutica Ag | Utilização de estatmina como um biomarcador da resposta farmacológica a furazanobenzimidazolos |
| DK2666016T3 (en) | 2011-01-21 | 2017-04-10 | Basilea Pharmaceutica Ag | USE OF BUBR1 AS A BIOMARKETER FOR PHARMACEUTICAL RESPONSE TO FURAZANOBENZIMIDAZOLES |
| CN103392130B (zh) * | 2011-02-24 | 2015-11-25 | 巴斯利尔药物股份公司 | 乙酰化微管蛋白作为对呋咱并苯并咪唑类的药物反应的生物标志物的用途 |
| PL2691533T3 (pl) * | 2011-03-29 | 2017-09-29 | Basilea Pharmaceutica Ag | Zastosowanie fosfo-Akt jako biomarkera odpowiedzi na leki |
| US9558575B2 (en) | 2012-02-28 | 2017-01-31 | Blackberry Limited | Methods and devices for selecting objects in images |
| ITRM20130248A1 (it) * | 2013-04-24 | 2014-10-25 | Medivis S R L | Formulazioni di riboflavina per il cross-linking transepiteliale. |
| WO2015173341A1 (en) * | 2014-05-13 | 2015-11-19 | Basilea Pharmaceutica Ag | Dosage principle for anti-cancer furazanylbenzimidazoles |
| US20180306790A1 (en) * | 2015-10-22 | 2018-10-25 | Basilea Pharmaceutica International AG | Use of eb1 as a biomarker of drug response |
| EP3612514B1 (en) * | 2017-04-20 | 2022-03-30 | PI Industries Ltd | Novel phenylamine compounds |
| KR20240038149A (ko) * | 2017-04-26 | 2024-03-22 | 바실리어 파마슈티카 인터내셔널 리미티드 | 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정 |
| EP3624790A1 (en) | 2017-05-16 | 2020-03-25 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| EP3853224A1 (en) | 2018-09-20 | 2021-07-28 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2021048135A1 (en) | 2019-09-09 | 2021-03-18 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| CN111454254B (zh) | 2020-04-26 | 2023-06-02 | 云白药征武科技(上海)有限公司 | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 |
| CN111423429A (zh) * | 2020-05-19 | 2020-07-17 | 江西科技师范大学 | 苯并咪唑联呋咱类系列化合物及其合成方法 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897208B2 (en) * | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| KR20040084896A (ko) * | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물 |
| JP4829791B2 (ja) * | 2003-05-23 | 2011-12-07 | バジリア ファルマスーチカ アーゲー | フラザノベンゾイミダゾール |
| WO2005077939A1 (en) * | 2004-02-11 | 2005-08-25 | Basilea Pharmaceutica Ag | Substituted benzimidazoles and their use for inducing apoptosis |
-
2010
- 2010-07-26 SI SI201030829T patent/SI2459553T1/sl unknown
- 2010-07-26 PT PT107401960T patent/PT2459553E/pt unknown
- 2010-07-26 ES ES10740196.0T patent/ES2524119T3/es active Active
- 2010-07-26 CN CN201080033104.2A patent/CN102471329B/zh active Active
- 2010-07-26 MX MX2012000611A patent/MX336240B/es unknown
- 2010-07-26 CA CA2767875A patent/CA2767875C/en active Active
- 2010-07-26 JP JP2012522131A patent/JP5576485B2/ja active Active
- 2010-07-26 PL PL10740196T patent/PL2459553T3/pl unknown
- 2010-07-26 KR KR1020127005138A patent/KR101758400B1/ko active IP Right Grant
- 2010-07-26 US US13/384,467 patent/US8802858B2/en active Active
- 2010-07-26 BR BR112012001817A patent/BR112012001817B8/pt active IP Right Grant
- 2010-07-26 EA EA201200189A patent/EA021380B1/ru unknown
- 2010-07-26 UA UAA201201704A patent/UA106763C2/uk unknown
- 2010-07-26 AU AU2010277688A patent/AU2010277688B2/en active Active
- 2010-07-26 DK DK10740196.0T patent/DK2459553T3/da active
- 2010-07-26 RS RS20140669A patent/RS53679B1/en unknown
- 2010-07-26 NZ NZ597376A patent/NZ597376A/en unknown
- 2010-07-26 WO PCT/EP2010/060803 patent/WO2011012577A1/en active Application Filing
- 2010-07-26 EP EP10740196.0A patent/EP2459553B1/en active Active
- 2010-07-27 TW TW099124742A patent/TWI457337B/zh active
-
2011
- 2011-12-25 IL IL217195A patent/IL217195A/en active IP Right Grant
-
2012
- 2012-01-11 ZA ZA2012/00228A patent/ZA201200228B/en unknown
- 2012-07-17 HK HK12106968.1A patent/HK1166316A1/xx unknown
-
2014
- 2014-11-19 HR HRP20141120AT patent/HRP20141120T1/hr unknown
- 2014-12-03 CY CY20141101010T patent/CY1115809T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1166316A1 (en) | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | |
| HK1182387A1 (en) | 1-substituted-carba-nucleoside prodrugs for antiviral treatment 1--carba- | |
| IL221055A0 (en) | Water treatment process | |
| HK1182688A1 (zh) | 水處理工藝 | |
| IL218683A0 (en) | Prodrugs of guanfacine | |
| EP2493820A4 (en) | WATER TREATMENT | |
| IL275350B (en) | Treatment of neoplastic diseases | |
| AP3665A (en) | Water treatment | |
| IL213673A0 (en) | Spiroindolinone derivative prodrugs | |
| ZA201300320B (en) | Purification process | |
| GB0904427D0 (en) | Treatment of diseases related to hyperactivity of the complement system | |
| IL214598A0 (en) | Water wheel | |
| SI2315743T1 (sl) | Postopek čiščenja dialkil sulfidov | |
| GB0900599D0 (en) | Treatment | |
| IL213919A0 (en) | Methods to treat cancer | |
| IL222610A0 (en) | Multifunctional locomotor | |
| GB0909963D0 (en) | Attachment to inline skates | |
| GB201001521D0 (en) | Treatment | |
| GB0913968D0 (en) | Treatment | |
| GB201006678D0 (en) | Inline drop-net | |
| GB0911469D0 (en) | Compounds to treat neurodegenerative disease | |
| GB0905127D0 (en) | Novel prodrugs | |
| GB0915307D0 (en) | Pond units | |
| GB0904178D0 (en) | General cure to diseases idea 3 | |
| EP2632259A4 (en) | HYPERSULATED DISACCHARIDES FOR THE TREATMENT OF ELASTASE-MEDIATED DISEASES |